UCSF

UC San Francisco Previously Published Works

Title

Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma.

Permalink

<https://escholarship.org/uc/item/44r1f8tr>

Journal

The pharmacogenomics journal, 15(5)

ISSN

1470-269X

Authors

Wang, Y
Tong, C
Wang, Z
et al.

Publication Date

2015-10-01

DOI

10.1038/tpj.2014.83

Peer reviewed

ORIGINAL ARTICLE

Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma

Y Wang^{1,7}, C Tong^{1,7}, Z Wang¹, Z Wang², D Mauger¹, KG Tantisira³, E Israel³, SJ Szeffler⁴, VM Chinchilli¹, HA Boushey⁵, SC Lazarus⁵, RF Lemanske⁶ and R Wu¹

Asthma is a chronic lung disease that has a high prevalence. The therapeutic intervention of this disease can be made more effective if genetic variability in patients' response to medications is implemented. However, a clear picture of the genetic architecture of asthma intervention response remains elusive. We conducted a genome-wide association study (GWAS) to identify drug response-associated genes for asthma, in which 909 622 SNPs were genotyped for 120 randomized participants who inhaled multiple doses of glucocorticoids. By integrating pharmacodynamic properties of drug reactions, we implemented a mechanistic model to analyze the GWAS data, enhancing the scope of inference about the genetic architecture of asthma intervention. Our pharmacodynamic model observed associations of genome-wide significance between dose-dependent response to inhaled glucocorticoids (measured as %FEV₁) and five loci ($P = 5.315 \times 10^{-7}$ to 3.924×10^{-9}), many of which map to metabolic genes related to lung function and asthma risk. All significant SNPs detected indicate a recessive effect, at which the homozygotes for the mutant alleles drive variability in %FEV₁. Significant associations were well replicated in three additional independent GWAS studies. Pooled together over these three trials, two SNPs, chr6 rs6924808 and chr11 rs1353649, display an increased significance level ($P = 6.661 \times 10^{-16}$ and 5.670×10^{-11}). Our study reveals a general picture of pharmacogenomic control for asthma intervention. The results obtained help to tailor an optimal dose for individual patients to treat asthma based on their genetic makeup.

The Pharmacogenomics Journal advance online publication, 20 January 2015; doi:10.1038/tpj.2014.83

INTRODUCTION

Asthma is a chronic lung disease characterized by recurring periods of wheezing, chest tightness, shortness of breath and coughing mediated through airway inflammation.¹ Given its substantial societal cost,² the discovery of any therapeutic intervention to treat this disease, especially severe asthma, has been a long-standing public health concern.^{3,4} Recent developments in molecular genetics provide an unprecedented opportunity to understand the genetic causes of asthma and identify targets that can be used to control the syndrome.^{4,5} More importantly, a systematic, large-scale survey of associations between common DNA sequence variants and disease has succeeded in identifying a set of specific genes that influence asthma.^{6–8} These asthma-associated genetic variants identified, distributed on various chromosomes, are found to affect this lung disease through altering key biochemical pathways that are related to lung function.^{9,10}

Although there is no doubt that the identification of genes for disease risk facilitates the development of effective medications for its treatment,¹¹ the efficient application of such medications will rely on our knowledge about pharmacogenomic effects on drug disposition, drug metabolism and drug response, given the fact that inter-individual variation exists in response to a particular drug.^{12,13} However, until recently, most pharmacogenomic studies have been carried out using candidate gene approaches. Specific

genes that encode enzymes involved in drug metabolism as well as drug targets, typically receptors or enzymes, have been identified. A successful example of candidate gene studies is the identification of genes that control the effect of anticoagulant drugs, such as warfarin.¹⁴ Some pharmacogenomic studies have also identified genes responsible for adverse drug reactions,¹² including those that encode metabolic enzymes and those that are related to the immune system and mitochondrial functions. In a recent review, Tse *et al.*¹⁵ described candidate genes and pathways detected thus far to control variability in response to three classes of asthma medications, β -adrenergic receptor agonists, inhaled corticosteroids and leukotriene modifiers.

Since 2007, genome-wide association studies (GWAS) have increasingly emerged as a powerful tool for pharmacogenomic studies. Significant associations through GWAS have been detected for the response to interferon- α ,^{16–18} clopidogrel¹⁹ and warfarin,^{20–22} as well as for adverse drug reactions related to statin-induced myopathy²³ and flucloxacillin-induced liver injury.²⁴ All these studies may help shed light on the genetic control mechanisms of drug response and their clinical implications.

Unlike a case in mapping complex diseases, GWAS of drug response is often characterized by a small size of samples¹² so that there may be insufficient power to detect small or moderate size effects. One approach to overcome this limitation is the use of

¹Division of Biostatistics and Bioinformatics, Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA; ²Division of Biostatistics, Yale School of Public Health, New Haven, CT, USA; ³Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; ⁴National Jewish Health and University of Colorado School of Medicine, Denver, CO, USA; ⁵Department of Medicine, University of California, San Francisco, CA, USA and ⁶Department of Medicine, University of Wisconsin, Madison, WI, USA. Correspondence: Professor R Wu or Professor D Mauger, Division of Biostatistics and Bioinformatics, Public Health Sciences, Penn State College of Medicine, Hershey, PA 17033, USA.

E-mail: rww@phs.psu.edu or dmauger@phs.psu.edu

⁷These authors contributed to this work equally.

Received 23 April 2014; revised 9 September 2014; accepted 7 November 2014

family-based data^{25–29} and has recently been applied to asthma treatment response.³⁰ However, the vast majority of clinical trials of drug response do not involve DNA collection in non-trial family participants. Here, we present an alternative approach by incorporating the pharmacodynamic principle of drug response into a pharmacogenetic GWAS. The basic idea of such incorporation is to model drug effect-dose relationships through mathematical equations based on repeated measures of drug response at multiple dosages.³⁰ By estimating and testing those mathematical parameters that define the effect-dose curves, one can determine how a specific gene affects drug effects at each dose or across a range of doses. Because of its statistical parsimony, that is, the number of curve parameters is always less than the number of doses,^{31–34} the incorporation of mathematical equations can potentially increase the power of detecting significant associations, compared with traditional GWAS analysis based on a simple phenotype-genotype relationship. Although the theory of this incorporation has well been established in the previous studies,^{30–34} here we have for the first time reported a systematic implication of this theory for practical pharmacogenetic studies in asthma intervention.

The pharmacodynamic approach was applied to analyze a pharmacological GWAS trial derived from SNP Health Association Asthma Resource projects (SHARP),^{35–37} leading to the identification of five significant SNPs responsible for pulmonary response after asthma treatment. Associations between these SNPs and the same phenotype were well confirmed by analyzing three additional GWAS. To investigate how small sample sizes, characteristic of pharmacogenomics studies, impact on the estimation of genetic effects and the power of gene detection, we performed computer simulation by mimicking the data structure of SHARP. We found that the implementation and use of a pharmacodynamic model can overcome, to some extent, the limitation of small sample sizes in pharmacological GWAS.

MATERIALS AND METHODS

Statistical design

Consider a clinical trial composed of n participants used for a pharmacological GWAS, in which each of the participants is genotyped for SNPs throughout the entire genome. These participants receive the administration of a drug under a multitude of doses, at each of which a pharmacological parameter that reflects drug effect is measured. Under this design, each participant (say i) has a series of dose-dependent pharmacological phenotypic data, expressed as $\mathbf{y}_i = (y_i(C_{i1}), \dots, y_i(C_{iM_i}))$, where $(C_{i1}, \dots, C_{iM_i})$ are M_i doses of administration participant i receives. We allow different participants to possibly receive different number of doses in the clinical trial.

It is likely that drug response as a complex trait is controlled by many genes, each with a different effect. The GWAS is motivated to identify all possible genes and estimate each gene's effects on drug response. Assuming that there is such a gene with three genotypes and, also, considering the influence on drug response by other covariates, such as race, sex, life style and age, the phenotypic value of participant i at dose m can be described by a regression model, expressed as,

$$y_i(C_{im}) = \sum_{j=1}^3 z_{ij} g_j(C_{im}) + \sum_{k=1}^K \alpha_k \mu_{ik} + \sum_{l=1}^L \sum_{s=1}^{S_l} x_{ils} v_{ls} + e_i(C_{im}) \quad (1)$$

where $g_j(C_{im})$ is the genotypic value of participant i who carries SNP genotype j at dose C_{im} ; z_{ij} is an indicator variable of participant i defined as 1 if this participant carries a genotype considered and 0 otherwise; μ_{ik} is the value of the k th ($k = 1, \dots, K$) continuous covariate for participant i ; α_k is the effect of the k th continuous covariate; v_{ls} is the effect of the l th ($l = 1, \dots, L$) discrete covariate at its s th ($s = 1, \dots, S_l$) level; x_{ils} is the indicator variable that describes the s th level of the l th discrete covariate for participant i and $e_i(C_{im})$ is a random error.

We implement a maximum likelihood approach to estimate the parameters involved in model (1). The likelihood of all participants is

constructed as:

$$L = \sum_{j=1}^3 \sum_{i=1}^{n_j} f_j(y_i) \quad (2)$$

where n_j is the number of participants with genotype j ; and $f_j(\mathbf{y}_i)$ is assumed to follow a multivariate normal distribution with mean vector for genotype j as:

$$\mu_{jji} = \left(g_j(C_{i1}) + \sum_{k=1}^K \alpha_k \mu_{ik} + \sum_{l=1}^L \sum_{s=1}^{S_l} x_{ils} v_{ls}, \dots, g_j(C_{iM_i}) + \sum_{k=1}^K \alpha_k \mu_{ik} + \sum_{l=1}^L \sum_{s=1}^{S_l} x_{ils} v_{ls} \right) \quad (3)$$

and covariance matrix

$$\Sigma_i = \begin{pmatrix} \sigma_{11}^2 & \dots & \sigma_{1M_i} \\ \vdots & \ddots & \vdots \\ \sigma_{M_i1} & \dots & \sigma_{M_i M_i}^2 \end{pmatrix} \quad (4)$$

We incorporated the pharmacodynamic model to estimate the genotypic values of a particular genotype j at different dosages,³⁰ as shown in (equation 2). Emax equation³⁸ that specifies drug effect E at a particular dose C is thought to be one of the most pharmacodynamics models, expressed as:

$$E(C) = E_0 + \frac{E_{\max} C^H}{EC_{50}^H + C^H} \quad (5)$$

where E_0 is the baseline, $E_{\max}$ is the asymptotic (limiting) effect, EC_{50} is the drug concentration that results in 50% of the maximal effect, and H is the slope parameter that determines the slope of the concentration-response curve. The larger H , the steeper the linear phase of the log-concentration effect curve. The phenotypic longitudinal data were normalized to remove the baseline so that drug effect at different levels of dosage is defined by three parameters. By estimating these parameters for different SNP genotypes, we could draw the curves of drug response for each genotype and test how different genotypes vary in the form of curve.

We used the $E_{\max}$ (equation 5) to model dose-dependent genotypic values for each SNP genotype j by pharmacological parameters ($E_{\max j}$, $EC_{50 j}$, H_j). In addition, considering the autocorrelation feature of the random error, we used the autoregressive regression model to estimate the across-dose covariance structure. Other approaches for modeling covariance structure are available in the literature,^{39–42} allowing a choice of the best fit model for a practical data set.

Hypothesis tests

Whether a particular gene affects drug response can be tested by a log-likelihood ratio approach. This can be done on the basis of two alternative hypotheses:

$$H_0: (E_{\max j}, EC_{50 j}, H_j) \equiv (E_{\max j}, EC_{50 j}, H_j) \quad (6)$$

H_1 : at least one of the equalities above does not hold

Under each hypothesis, we calculate the likelihood and further calculate their ratio. This ratio is thought of being χ^2 distributed with six degrees of freedom.

After a gene is confirmed to be significant among its three genotypes, we will further test how this gene acts to affect drug response. The action of a gene can be additive, dominant or recessive. Wu et al.³⁰ provided a general procedure to test the mode of action under a pharmacodynamic model. A SNP is first analyzed by a genotypic model, that is, testing differences among three genotypes based on hypothesis test (6), followed by the additive and dominant/recessive tests. We used model selection criteria, such as BIC, to choose an optimal model.

Samples

The research with human participants has been approved by Penn State College of Medicine's Review Board. Table 1 summarizes key population characteristics of several trials used for GWAS analysis. In the dose of inhaled corticosteroids with equisystemic effects (DICE) trial,³⁵ 120 randomized participants (post-pubertal to 60 years of age) were recruited with mild-to-moderate asthma, defined as 12% change in forced expiratory volume in 1 s (FEV₁) or ≤ 8 mg ml⁻¹ methacholine provocative concentration causing a 20% drop in FEV₁ (PC₂₀) and baseline FEV₁ 65–90% of

Table 1. Population characteristics of the longitudinal DICE trial and other three independent trials

Characteristic	DICE	IMPACT	SOCS	SLIC	SOCS/SLIC
No. of subjects	120	251	79	106	31
Inhaled glucocorticoid	Budesonide	1) Budesonide 2) Prednisone+ Budesonid+ Zafirlukast	Triamcinolone	1) Triamcinolone 2) Salmeterol+ Triamcinolone	Triamcinolone
Age (year)	30.6 ± 8.1	34.2 ± 10.8	30.4 ± 10.9	35.9 ± 12.4	32.7 ± 11.4
Sex no. subject(%)					
Male	51 (56.7%)	57 (39.0%)	30 (41.1%)	43 (45.3%)	11 (52.4%)
Female	39 (43.3%)	89 (61.0%)	43 (58.9%)	52 (54.7%)	10 (47.6%)
Baseline FEV ₁ (%) of predicted	79.0 ± 7.4	88.8 ± 13.3	85.6 ± 14.0	67.6 ± 10.9	73 ± 15.9
Change in FEV ₁ (%)	6.5 ± 10.3	1.3 ± 7.4	7.3 ± 11.8	4.5 ± 9.8	2.6 ± 16.6

predicted. During enrollment, AM (before 0930 hours) plasma cortisol concentration of ≥ 5 mcg dl⁻¹ need to be attained. After a 1-week run-in period, participants were randomized to one of six active inhaled corticosteroid (ICS) delivery systems (or the corresponding placebo). After each week of treatment, participants remained at the study center for an overnight stay and then received a medication supply with a doubled dose for the subsequent week. This process continues until there are a total of four dosages. At each of the dosages, participants were measured for the percent predicted value of the pre-bronchodilator forced expiratory volume in 1s (%FEV₁).

The IMPACT trial³⁵ includes 225 adult asthma participants (in age 18–65 years with mild, persistent asthma) with FEV₁ $\geq 70\%$ of predicted, displaying either $\geq 12\%$ or >200 ml improvement following albuterol inhalation or bronchial hyper-reactivity (methacholine PC₂₀ < 16 mg ml⁻¹). All participants were instructed to take open-label budesonide or prednisone as guided by the symptom-based action plan. The run-in and treatment phases both ended with a 14-day period of intense combined therapy. Salmeterol off corticosteroids (SOCS)³⁶ and salmeterol ± inhaled corticosteroids (SLIC) trials³⁷ include 79 and 106 asthma participants, respectively, which were conducted in tandem with a common 6-week run-in period on inhaled corticosteroid therapy (Table 1). At the end of the run-in period, the milder patients were allocated to SOCS (FEV₁ $>80\%$ predicted, PEF variability $\approx 20\%$) and the more moderate patients allocated to SLIC. The %FEV₁ was measured for the three trials above.

In four trials, DICE, IMPACT, SOCS and SLIC, subjects were genotyped for 909 622 SNPs throughout the entire genome. Genotyping was performed on Affymetrix 6.0 arrays. SNP genotypes were obtained after stringent quality-control filters.

RESULTS

Gene detection

We used the pharmacodynamic model to identify genes for drug response (%FEV₁) to inhaled corticosteroids for asthma treatment by jointing estimating the effect due to covariates, age, BMI, race, gender and drug type. Dose levels of drugs were normalized to a range from 0 to 1. We implemented four genetic models to study the patterns of pharmacological inheritance: (1) genotypic model detecting the overall effect due to differences among three SNP genotypes, (2) additive model detecting the effect due to the substitution of the wild-type allele (common) by the mutant (minor), (3) dominant model in which the mutant allele is dominant over the wild-type allele and (4) recessive model in which the expression of the mutant is masked by the wild-type allele. We excluded those SNPs from our GWAS analysis with minor allele frequency < 0.3 ; this threshold is larger than usual, aimed to assure sufficient samples for each genotype group given our modest sample size. To the end, a total of 266 944 SNPs were involved in the analysis.

The four genetic models were each used to scan SNPs throughout the entire genome for the DICE trial. After the Bonferroni correction,

Table 2. Power to correctly identify the pattern of pharmacological inheritance by the pharmacodynamic model

Sample size	True model	Estimated model			
		Full	Recessive	Dominant	Allelic
100	Full	887	106	7	0
	Recessive	1	993	1	5
	Dominant	0	0	954	46
	Additive	4	63	69	864
200	Full	991	9	0	0
	Recessive	14	986	0	0
	Dominant	5	0	983	12
	Additive	9	10	18	963
400	Full	1000	0	0	0
	Recessive	16	984	0	0
	Dominant	8	0	990	2
	Additive	2	1	1	996

The data were simulated by mimicking the DICE data structure and the estimates obtained by BIC from 1000 simulation replicates.

five significant SNPs were detected by the genotypic (Supplementary Figure 1A) and recessive model (Supplementary Figure 1D). The additive and dominant models did not identify significant associations (Supplementary Figure 1B and 1C). Two SNPs on chromosomes 8 and 11 were detected by both genotypic and recessive models, but, according to BIC values calculated, both SNPs conform to the recessive model better than the genotypic model. The following loci produce associations of genome-wide significance with physiological response to glucocorticoid therapy for asthma (Table 2); rs6924808 on chromosome 6 with wild-type allele C and mutant T ($P=5.315 \times 10^{-7}$), rs10481450 on chromosome 8 with wild-type allele A and mutant T ($P=2.614 \times 10^{-8}$), rs1353649 on chromosome 11 with wild-type allele G and mutant A ($P=3.924 \times 10^{-9}$), rs12438740 on chromosome 15 with wild-type allele C and mutant T ($P=4.499 \times 10^{-8}$), and rs2230155 on chromosome 15 with wild-type allele C and mutant T ($P=1.798 \times 10^{-7}$). To evaluate the influence of population stratification, we calculated the ratio of the median of the log-likelihood ratios among all SNPs analyzed over the critical value of the χ^2 distribution at the 0.05 significance level. If this ratio is near, or slightly less than, 1.0, this indicates that the effect due to population stratification is ignorable.⁴³ The ratios calculated are 0.82–0.88 for the genotypic, additive and dominant models used, suggesting that our results are not largely affected by population structure.

Figure 1. Changes in pulmonary response to varying doses of inhaled corticosteroids as defined as prebronchodilator %FEV₁ for two different groups of genotypes (i.e., the mutant homozygote, MM and a mix of the homozygote for the wild-type allele and the heterozygote for the two different alleles, W₁) at five significant SNPs, chr6 rs6924808 (a), chr8 rs10481450 (b), chr11 rs1353649 (c), chr15 rs12438740 (d) and chr15 rs2230155 (e), for the DICE trial detected by the recessive model. Blue thin lines in background are response curves of individual participants to varying dosages. The original data were normalized by removing the baselines and plotted against relative scales of corticosteroid dosages.

Pharmacodynamic pattern of genetic effects

The pharmacodynamic model allows the estimates of genotype-specific curve parameters ($E_{\max}$, EC_{50} , H) that define drug response (see Supplementary Table 1 for the maximum likelihood estimates of the parameters and the s.d. of the estimates). Each of these parameters differs strikingly between two groups of genotypes, the homozygote for the mutant allele, and a mix of the homozygote for the wild-type allele and the heterozygote for the two different alleles, at significant SNPs. The overall influence of these parameters on variability in glucocorticoid response curve can be seen from response curves drawn for each genotype group (Figure 1). It can be observed that individual SNPs fit raw longitudinal data reasonably well and also different SNPs affect drug response in different ways.

At all significant SNPs, the wild-type allele is dominant over the mutant for their actions in affecting glucocorticoid response, as revealed by the recessive model (Table 2). For chr6 rs6924808, the homozygote (CC) for the wild-type allele C and the heterozygote (CT) for the wild-type allele and mutant T are more responsive to changing doses of glucocorticoids than the homozygote (TT) for the mutant (Figure 1a). At chr8 rs10481450 and chr11 rs1353649, the homozygotes for the mutant display remarkably greater sensitivity to drug dose than the genotypes containing the wild-type alleles (Figures 1b and c). Chr15 rs12438740 and chr15 rs2230155 are located closely together on the same chromosome, with a high

linkage disequilibrium ($r=0.99$), exhibit a similar dynamic pattern of genetic effect (Figures 1d and e); the homozygote for the mutant do not respond until a particular dose level is reached, whereas the genotypes containing the wild-type allele appear to be resistant to increasing dose. Figure 1 shows that some SNPs capture a wide variation like rs10481450 and rs1353649, whereas the others explain a narrow variation like rs6924808, rs12438740 and rs2230155. Some SNPs are sensitive to a small change in low doses of drug, such as rs6924808, and some display variation after a certain level of dose is reached, such as rs10481450 and rs12438740. The common feature of all the SNPs is that different groups of genotypes start to diverge at a lower level of dose and stabilize their variation during a wide range of dose.

In sum, the mutant allele produces a pronounced increase in lung function after glucocorticoid treatment as compared with the wild-type allele for all SNPs, except for chr6 rs6924808. Overall, subjects who are homozygous for the mutant allele are 30–300% larger for %FEV₁ values at an intermediate dose of glucocorticoids than those who are homozygous for the wild-type allele and heterozygous for the two alleles (Figure 2; Supplementary Table 2). The differences between these two groups of genotypes are 30–245% of the mean of all treated subjects. There are striking differences in the heritability of %FEV₁ response to glucocorticoid therapy explained by individual SNPs (Figure 3). Chr11 rs1353649 accounts for 19–26% of the phenotypic variation, whereas these

Figure 2. Changes of normalized %FEV₁ mean ($\pm$ s.e.) by the mutant homozygote (MM) over a mix of the homozygote for the wild-type allele and the heterozygote for the two different alleles (W₋) at an intermediate dose of glucocorticoids for significant SNPs, chr6 rs6924808 (a), chr8 rs10481450 (b), chr11 rs1353649 (c), chr15 rs12438740 (d), and chr15 rs2230155 (e), for the DICE trial detected by the recessive model.

values are 8–20% for chr8 rs10481450 and chr6 rs6924808 and 2–5% for chr15 rs12438740 and chr15 rs2230155. All SNPs display a dynamic change of heritability over dose.

Cross validation

We performed an additional analysis to cross-validate the results detected by randomly splitting the population into two equally sized sub-groups. In Supplementary Table 3, we summarized the results about the estimates of parameters from 100 resampling replicates for each subgroup at a significant SNP rs10481450, in a comparison with those from the whole population. The parameter estimates of each subgroup are quite consistent, and they are consistent with those using the whole population. Although s.e. values of the estimates for some parameters are large due to a small sample size, they are reasonably within the space of estimates.

Computer Simulation

The statistical properties of the pharmacodynamic model to analyze GWAS data were investigated through computer simulation. The simulation mimicked the DICE trial in terms of sample size, dose level and demographical attributes of participants. The phenotypic data of drug response were simulated using parameters estimated for SNP rs10481450 detected from the DICE trial by assuming normally distributed residuals. The data were simulated using the genotypic, additive, dominant and recessive models and then analyzed by each model.

The pharmacological model has good power to detect a correct pattern of genetic action (Table 2). When a correct model was used, genotype-specific pharmacodynamic parameters and covariate effects can be reasonably estimated. Table 3 gives the estimates of parameters and their sampling errors under different sample sizes when the genotypic model is assumed. In Supplementary Table 4, estimates of parameters by the dominant, recessive and additive models are given. The estimates of three pharmacological parameters, $E_{\max}$, EC_{50} and H , each have a reasonably small sampling error for each genotype, even when the sample size is modest (100). The estimation precision of these parameters increases markedly when sample size increases to 200 or 400.

Because humans cannot be controlled, like plants or animals, it is unavoidable to include many covariates, such as different demographic factors, in human GWAS. These covariates would often confound the identification of significant genes. However, the deployment of a multiple regression model that incorporates covariate effects can filter some of these confounders. As shown in Table 4, the estimates of genotype-specific pharmacodynamics parameters are not affected by covariates. Furthermore, model (1)

Figure 3. Dynamic changes of the heritability for %FEV₁ over relative scales of corticosteroid dosages explained by individual SNPs, chr6 rs6924808 (a), chr8 rs10481450 (b), chr11 rs1353649 (c), chr15 rs12438740 (d) and chr15 rs2230155 (e) for the DICE trial.

Table 3. Means of the estimates of parameters for the pharmacodynamic approach and their s.e. values (in parentheses) from simulated data by mimicking the DICE data structure with different sample sizes based on 1000 simulation replicates (full genotypic model)

Parameter	True Value	Sample Size		
		100	200	400
$E_{\max 1}$	9.934	10.511 (1.653)	10.465 (1.417)	10.332 (1.167)
H_1	1.472	1.441 (0.589)	1.435 (0.562)	1.455 (0.517)
$EC_{50(1)}$	0.069	0.094 (0.089)	0.082 (0.050)	0.076 (0.024)
$E_{\max 2}$	17.637	17.317 (2.539)	17.515 (2.228)	17.668 (1.884)
H_2	2.509	2.864 (0.796)	2.723 (0.662)	2.618 (0.477)
$EC_{50(2)}$	0.551	0.544 (0.091)	0.549 (0.068)	0.552 (0.053)
$E_{\max 3}$	19.858	20.185 (2.422)	20.060 (2.019)	19.976 (1.567)
H_3	2.2	2.580 (0.955)	2.430 (0.779)	2.340 (0.583)
$EC_{50(3)}$	0.13	0.144 (0.047)	0.137 (0.028)	0.134 (0.019)
α_1	-0.075	-0.077 (0.086)	-0.074 (0.058)	-0.074 (0.040)
α_2	0.113	0.116 (0.109)	0.111 (0.072)	0.112 (0.050)
v_{11}	2.135	2.178 (1.100)	2.150 (0.775)	2.117 (0.527)
v_{12}	-1.065	-1.074 (1.407)	-1.104 (0.966)	-1.104 (0.681)
v_{13}	-3.553	-3.531 (1.427)	-3.532 (0.944)	-3.521 (0.668)
v_{14}	3.037	2.978 (1.641)	3.014 (1.124)	3.039 (0.822)
v_{21}	3.855	3.943 (1.666)	3.925 (0.956)	3.872 (0.627)
v_{22}	-6.059	-6.031 (2.081)	-6.039 (1.279)	-6.044 (0.874)
v_{23}	4.904	5.001 (2.418)	4.943 (1.417)	4.902 (0.998)
v_{31}	-0.798	-0.829 (0.699)	-0.814 (0.464)	-0.816 (0.322)
ρ	0.754	0.738 (0.027)	0.746 (0.020)	0.750 (0.014)
σ^2	71.401	66.294 (6.071)	68.769 (4.415)	69.995 (3.103)

Note: α_1 and α_2 are the effects due to two continuous covariates, v_1 , v_2 and v_3 are the effects due to three discrete covariates each with a different level and ρ and σ^2 are the autoregressive parameters that model the covariance structure.

can provide an estimate of the effects of each covariates including continuous and discrete. Estimates of some of the covariate effects are not very precise under a small sample size (100), but this situation can improve dramatically when the sample size increases to 400.

Wu *et al.*³⁰ showed that the pharmacodynamics model displays increased power of gene detection compared to traditional GWAS

Table 4. Significant SNPs detected for inhaled corticosteroid drug response to asthma treatment from the DICE trials and confirmed in three additional trials

Model	SNP	Chr	Position	Alleles	MAF	P-value				
						DICE	IMPACT	SOCS	SLIC	Pooled
Recessive	rs6924808	6	98465296	C/T	0.477 (T)	5.315×10^{-7}	5.908×10^{-11}	0.034	0.001	6.661×10^{-16a}
Recessive	rs10481450	8	9835656	A/T	0.310 (T)	2.614×10^{-8}	0.072	0.057	1.154×10^{-6}	0.023
Recessive	rs1353649	11	20210175	A/G	0.320 (A)	3.924×10^{-9}	0.003	0.089	0.024	5.670×10^{-11a}
Recessive	rs12438740	15	57303059	C/T	0.348 (T)	4.499×10^{-8}	0.004	0.0003	2.883×10^{-5}	0.040
Recessive	rs2230155	15	57297481	C/T	0.350 (T)	1.798×10^{-7}	0.043	0.211	0.056	0.132

The chromosomal positions, alleles, minor allele (in parentheses) frequencies (MAF), and significance levels of these SNPs are given. ^aThese P-values were obtained from an optimal model, genotypic model.

Figure 4. Changes of %FEV₁ mean ($\pm$ s.e.) by the mutant homozygote (MM) over a mix of the homozygote for the wild-type allele and the heterozygote for the two different alleles (W₁) at an intermediate dose of glucocorticoids for significant SNPs, chr6 rs6924808 (a), chr8 rs10481450 (b), chr11 rs1353649 (c), chr15 rs12438740 (d), and chr15 rs2230155 (e), for pooled IMPACT, SOCS and SLIC trials detected by the recessive model. Note that %FEV₁ was not normalized because these trials contain only one dose of glucocorticoids.

analysis based on a single static phenotype. To confirm their result, we used the simulated data above that mimics the DICE trial to estimate the empirical power of gene detection at each of four doses. This power was observed to be substantially lower (by 1.5–8.5 times) than the power of gene detection by the pharmacodynamics model that makes use of data at all doses at one time, consistent with Wu *et al.*'s finding.

Replication

Here, we used three other trials to validate the results. These trials are the IMProving Asthma Control Trial (IMPACT),³⁵ Salmeterol Off CorticoSteroids (SOCS) trial,³⁶ and Salmeterol $\pm$ Inhaled Corticosteroids (SLIC) trials.³⁷ Because of one single dose of corticosteroid used, we analyzed associations between %FEV₁ values and five significant SNPs detected from DICE using a univariate model (Table 4). All the five SNPs were found to be significant in the three trials, except for chr15 rs2230155 being non-significant for SOCS and chr8 rs10481450 and chr11 rs1353649 being marginally significant for IMPACT and SOCS, respectively (Table 4). Pooled together over IMPACT, SOCS, and SLIC of a similar design, all SNPs, except for chr15 rs2230155, display significant associations with glucocorticoid response. Figure 4 compares the differences of %FEV₁ between two groups of genotypes, the mutant homozygote and a mix of the homozygote for the wild-type allele and the heterozygote for the two different alleles, at each SNP for the pooled three trials. For chr6 rs6924808 and chr11 rs1353649, such differences have different directions between the pooled trials and DICE. When an optimal model, i.e., genotypic model, was

used, these two SNPs produce a very high level of significance for associations ($P = 6.661 \times 10^{-16}$ and 5.670×10^{-11} ; Table 4).

DISCUSSION

The pharmacodynamic model has successfully detected five loci of significant effects on response curves of corticosteroids for asthma by integrating the biochemical processes of drug response into GWAS. This integration has proven to be statistically more powerful for gene detection than traditional approaches based on a single dose.³⁰ The identification of significant SNPs by our model has been validated by resampling and simulation studies. Furthermore, these five SNPs demonstrate good replication in three independent clinical trial populations for the same phenotype. In general, the mutant alleles at most SNPs tend to increase pulmonary function of asthma participants by 30–300% after inhaled glucocorticoid treatment relative to the wild-type alleles, although the expression of the mutant may be masked by the wild-type allele. In another study, Tantisira *et al.*²⁹ found that the mutant homozygote at chr7 rs37972 displays 120–330% decrease of lung function through glucocorticoid treatment compared with the wild-type homozygote. In both studies by us and Tantisira *et al.*, the heritabilities of glucocorticoid response explained by individual SNPs are much larger than those detected for disease and physiological traits.^{8–11} This may be due to the fact that drug response is evolutionarily a 'young' trait, which has not experienced yet a long history of natural selection as the other traits have.¹²

High heritability detection should benefit from the statistical merit of our pharmacodynamic model that was derived from parsimonious modeling of the mean-covariance structures for longitudinal data of drug response across a series of doses. For example, four parameters are needed to describe drug response of a genotype at four dose levels if traditional approaches are used, while the pharmacodynamic model only uses three parameters to do the same thing. Moreover, the pharmacodynamic model, such as the Emax model³⁶ and differential equations,^{44,45} contains biologically meaningful aspects of drug response in terms of body–drug interactions. Applied to GWAS of response to corticosteroids for asthma intervention, this model can not only facilitate the interpretation and elucidation of the pharmacogenomics architecture of this important clinical problem, but also increase the statistical power of significant association detection.

Except for SNP rs6924808 on chromosome 6, the other four detected are located in the vicinity of candidate genes associated with cellular functions. It appears that SNP rs10481450 on chromosome 8 is related to gene *TNKS*, a PARP member localized predominantly in the cytosol, that regulates cellular viability and NAD(+) metabolism⁴⁶ and gene *MSRA* that has a function to repair oxidative damage to proteins to restore biological activity.⁴⁷ SNP rs1353649 on chromosome 11 is nearby many candidate genes, such as *DBX1*,⁴⁸ *NAV2*,⁴⁹ *HTATIP2*⁵⁰ and *PRMT3*,⁵¹ some of which

determine nicotine dependence. MYO1E is also a nicotine dependence-related gene⁵² in which two associated SNPs, rs12438740 and rs2230155, on chromosome 15 were identified.

A modest sample size used may overestimate genetic effects of SNPs. However, our pharmacodynamic model makes use of the longitudinal feature of phenotypic data measured repeatedly for the same subjects, which has proven to be powerful for increasing the precision of parameter estimation.³⁰ Our finding here shows a promise to utilize the genetic results obtained to predict individual patients' performance in asthma intervention. Recent studies showed that asthma may be affected by DNA methylation through regulating gene expression.⁵³ It is straightforward to integrate methylation variants into the model to better reveal the genetic and epigenetic basis of asthma intervention. To the end, by incorporating our new model with genetic and epigenetic observations for asthma^{6,7} and associated alteration in lung function by asthma,^{9,10} we may better determine and design the optimal doses for individual patients,¹³ maximizing drug efficacy for optimal pulmonary function response while minimizing drug toxicity.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank Kwangmi Ahn for her assistance in data management. This research was funded by grants NIH/NHLBI-1U10HL098115, UL1 TR000127, U10 HL-51810, U10 HL-51834, U10 HL-51831, U10 HL-51823, U10 HL-51845, U10 HL-51843, and U10 HL-56443. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

REFERENCES

- 1 Fanta CH. Asthma. *N Engl J Med* 2009; **360**: 1002–1014.
- 2 Szefer SJ. Advancing asthma care: the glass is only half full. *J Allergy Immunol* 2011; **128**: 485–494.
- 3 Apter AJ. Advances in adult asthma diagnosis and treatment and HEDQ in 2010. *J Allergy Clin Immunol* 2011; **127**: 116–122.
- 4 National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. NIH Publication no. 07-4051. Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/index.htm>. Accessed July 16, 2011.
- 5 Yoshihara S. Early intervention for infantile and childhood asthma. *Expert Rev Clin Immunol* 2010; **6**: 247–255.
- 6 Bouzigon E, Corda E, Aschard H, Dizier MH, Boland A, Bousquet J *et al*. Effect of 17q21 variants and smoking exposure in early-onset asthma. *N Engl J Med* 2008; **359**: 1985–1994.
- 7 Moffatt MF, Kabisch M, Liang L, Dixon AL, Strachan D, Heath S *et al*. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. *Nature* 2007; **448**: 470–473.
- 8 Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S *et al*. A large-scale, consortium-based genome-wide association study of asthma. *N Engl J Med* 2010; **363**: 1211–1221.
- 9 Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M *et al*. Genome-wide association study identifies five loci associated with lung function. *Nat Genet* 2010; **42**: 36–44.
- 10 Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loefer LR, Marciano KD *et al*. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat Genet* 2010; **42**: 45–52.
- 11 Manolio TA. Genome-wide association studies and assessment of the risk of disease. *N Engl J Med* 2010; **363**: 166–176.
- 12 Daly AK. Genome-wide association studies in pharmacogenomics. *Nat Rev Genet* 2010; **11**: 241–246.
- 13 Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT *et al*. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med* 2009; **360**: 753–764.
- 14 Daly AK. Pharmacogenomics of anticoagulants: steps toward personal dosage. *Genome Med* 2009; **1**: 10.

- 15 Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. *Pharmacogenomics J* 2011; **11**: 383–392.
- 16 Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ *et al*. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009; **461**: 399–401.
- 17 Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML *et al*. IL28B is associated with response to chronic hepatitis C interferon- α and ribavirin therapy. *Nat Genet* 2009; **41**: 1100–1104.
- 18 Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N *et al*. Genome-wide association of IL28B with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009; **41**: 1105–1109.
- 19 Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB *et al*. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA* 2009; **302**: 849–857.
- 20 Cooper GM, Johnson JA, Langae TY, Feng H, Stanaway IB, Schwarz UI *et al*. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. *Blood* 2008; **112**: 1022–1027.
- 21 Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A *et al*. A genome-wide association study of acenocoumarol maintenance dosage. *Hum Mol Genet* 2009; **18**: 3758–3768.
- 22 Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N *et al*. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. *PLoS Genet* 2009; **5**: e1000433.
- 23 SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F *et al*. SLC6A1 variants and statin-induced myopathy – a genome-wide study. *N Engl J Med* 2008; **359**: 789–799.
- 24 Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A *et al*. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet* 2009; **41**: 816–819.
- 25 Van Steen K, McQueen MB, Herbert A, Raby B, Lyon H, Demeo DL *et al*. Genomic screening and replication using the same data set in family based association testing. *Nat Genet* 2005; **37**: 683–691.
- 26 Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeuffer A, Illig T *et al*. A common genetic variant is associated with adult and childhood obesity. *Science* 2006; **312**: 279–283.
- 27 Lasky-Su J, Lyon HN, Emilsson V, Heid IM, Molony C, Raby BA *et al*. On the replication of genetic associations: timing can be everything!. *Am J Hum Genet* 2008; **82**: 849–858.
- 28 Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF *et al*. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet* 2008; **83**: 623–632.
- 29 Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE *et al*. Genome-wide association between GLCCI1 and response to glucocorticoid therapy in asthma. *N Engl J Med* 2011; **365**: 1173–1183.
- 30 Wu RL, Tong CF, Mauger D, Mauger D, Tantisira K, Szefer SJ *et al*. A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. *Drug Discov Today* 2011; **16**: 804–890.
- 31 Gong Y, Wang Z, Liu T, Zhao W, Zhu Y, Johnson JA *et al*. A statistical model for functional mapping of quantitative trait loci regulating drug response. *Pharmacogenomics J* 2004; **4**: 315–321.
- 32 Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. *Pharmacogenomics J* 2005; **5**: 149–156.
- 33 Lin M, Hou W, Li HY, Johnson JA, Wu R. Modeling sequence-sequence interactions for drug response. *Bioinformatics* 2007; **23**: 1251–1257.
- 34 Wu RL, Lin M. *Statistical and Computational Pharmacogenomics*. Chapman & Hall/CRC: London, 2008.
- 35 Martin RJ, Szefer SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA *et al*. Systemic effect comparisons of six inhaled corticosteroid preparations. *Am J Respir Crit Care Med* 2002; **165**: 1377–1383.
- 36 Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC *et al*. Regular vs. intermittent controller therapy for mild persistent asthma. *N Engl J Med* 2005; **352**: 1519–1528.
- 37 Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA *et al*. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. *JAMA* 2001; **285**: 2583–2593.
- 38 Giraldo J. Empirical models and Hill coefficients. *Trend Pharmacol Sci* 2003; **24**: 63–65.
- 39 Diggle PJ, Heagerty P, Liang KY *et al*. *Analysis of Longitudinal Data*. Oxford University Press: Oxford, UK, 2002.
- 40 Zimmerman DL, Nunez-Anton V. Parametric modeling of growth curve data: an overview (with discussion). *Test* 2001; **10**: 1–73.
- 41 Zhao W, Hou W, Littell RC, Wu R. Structured antedependence models for functional mapping of multivariate longitudinal quantitative traits. *Stat Appl Mol Genet Biol* 2005; **4**: Article 33.

- 42 Yap JS, Li Y, Das K, Li J, Wu R. Functional mapping of reaction norms to multiple environmental signals through nonparametric covariance estimation. *BMC Plant Biol* 2011; **11**: 23.
- 43 Devlin B, Roeder K. Genomic control for association studies. *Biometrics* 1999; **55**: 997–1004.
- 44 Mustavich LF, Miller P, Kidd KK, Zhao H. Using a pharmacokinetic model to relate an individual's susceptibility to alcohol dependence to genotypes. *Hum Hered* 2010; **70**: 177–193.
- 45 Ahn K, Luo JT, Berg A, Keefe D, Wu R. Functional mapping of drug response with pharmacodynamic-pharmacokinetic principles. *Trend Pharmacol Sci* 2010; **31**: 306–311.
- 46 Yeh TY, Sbodio JI, Nguyen MT, Meyer TN, Lee RM, Chi NW. Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1. *Mol Cell Biochem* 2005; **276**: 183–192.
- 47 Kuschel L, Hansel A, Schonherr R, Weissbach H, Brot N, Hoshi T *et al*. Molecular cloning and functional expression of a human peptide methionine sulfoxide reductase (hMsRA). *FEBS Lett* 1999; **456**: 17–21.
- 48 Lanuza GM, Gosgnach S, Pierani A, Jessell TM, Goulding M. Genetic identification of spinal interneurons that coordinate left-right locomotor activity necessary for walking movements. *Neuron* 2004; **42**: 375–386.
- 49 Maes T, Barcelo A, Buesa C. Neuron navigator: a human gene family with homology to unc-53, a cell guidance gene from *Caenorhabditis elegans*. *Genomics* 2002; **80**: 21–30.
- 50 Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, Favia AD *et al*. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. *Chem Biol Interact* 2009; **178**: 94–98.
- 51 Tang J, Gary JD, Clarke S, Herschman HR. PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. *J Biol Chem* 1998; **273**: 16935–16945.
- 52 Hasson T, Skowron JF, Gilbert DJ, Avraham KB, Perry WL, Bement WM *et al*. Mapping of unconventional myosins in mouse and human. *Genomics* 1997; **36**: 431–439.
- 53 Rastogi D, Suzuki M, Greally JM. Differential epigenome-wide DNA methylation patterns in childhood obesity-associated asthma. *Sci Rep* 2013; **3**: 2164.

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (<http://www.nature.com/tpj>)